Do analysts recommend CNSP or PTPI?

CNS Pharmaceuticals currently has a consensus target price of $20.00, indicating a potential upside of 327.35%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Petros Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CNSP or PTPI more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -238.68% -166.30% Petros Pharmaceuticals N/A -78.22% -23.50%

Do analysts recommend CNSP or TAOX?

CNS Pharmaceuticals presently has a consensus price target of $20.00, indicating a potential upside of 327.35%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe CNS Pharmaceuticals is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CNSP or TAOX more profitable?

Synaptogenix's return on equity of -163.40% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -238.68% -166.30% Synaptogenix N/A -163.40% -133.47%

Which has higher valuation and earnings, CNSP or KALA?

CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CNS Pharmaceuticals N/A N/A -$15.85M -$29.63 N/A KALA BIO N/A N/A -$26.98M -$96.14 N/A

Is CNSP or KALA more profitable?

CNS Pharmaceuticals' return on equity of -238.68% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -238.68% -166.30% KALA BIO N/A -1,336.10% -94.85%

Is CNSP or EVAX more profitable?

Evaxion A/S's return on equity of -73.56% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -238.68% -166.30% Evaxion A/S N/A -73.56% -37.45%

CNS Pharmaceuticals (CNSP) Competitors

$4.68 -0.18 (-3.70%)

Closing price 03:58 PM Eastern

Extended Trading

$4.70 +0.03 (+0.53%)

As of 04:37 PM Eastern

Compare

CNSP vs. PTPI, TAOX, KALA, CPHI, and EVAX

Should you buy CNS Pharmaceuticals stock or one of its competitors? MarketBeat compares CNS Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CNS Pharmaceuticals include Petros Pharmaceuticals (PTPI), Synaptogenix (TAOX), KALA BIO (KALA), China Pharma (CPHI), and Evaxion A/S (EVAX). These companies are all part of the "pharmaceutical products" industry.

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

CNS Pharmaceuticals (NASDAQ:CNSP) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

CNS Pharmaceuticals has a beta of 3.06, meaning that its stock price is 206% more volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.86, meaning that its stock price is 86% more volatile than the broader market.

Petros Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A
Petros Pharmaceuticals	$5.11M	0.03	-$8.16M	-$1.64	N/A

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 0.0% of CNS Pharmaceuticals shares are owned by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, CNS Pharmaceuticals had 1 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 1 mentions for CNS Pharmaceuticals and 0 mentions for Petros Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.93 beat Petros Pharmaceuticals' score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CNS Pharmaceuticals	Positive
Petros Pharmaceuticals	Neutral

CNS Pharmaceuticals currently has a consensus target price of $20.00, indicating a potential upside of 327.35%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Petros Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Summary

CNS Pharmaceuticals and Petros Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Synaptogenix?

CNS Pharmaceuticals (NASDAQ:CNSP) and Synaptogenix (NASDAQ:TAOX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

CNS Pharmaceuticals has a beta of 3.06, indicating that its share price is 206% more volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market.

In the previous week, CNS Pharmaceuticals and CNS Pharmaceuticals both had 1 articles in the media. Synaptogenix's average media sentiment score of 0.94 beat CNS Pharmaceuticals' score of 0.93 indicating that Synaptogenix is being referred to more favorably in the news media.

Company	Overall Sentiment
CNS Pharmaceuticals	Positive
Synaptogenix	Positive

14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 0.0% of CNS Pharmaceuticals shares are held by insiders. Comparatively, 2.7% of Synaptogenix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Synaptogenix's return on equity of -163.40% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
Synaptogenix	N/A	-163.40%	-133.47%

CNS Pharmaceuticals presently has a consensus price target of $20.00, indicating a potential upside of 327.35%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe CNS Pharmaceuticals is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CNS Pharmaceuticals has higher earnings, but lower revenue than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A
Synaptogenix	$300K	95.37	-$28.74M	-$13.28	N/A

Summary

CNS Pharmaceuticals beats Synaptogenix on 7 of the 13 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to KALA BIO?

CNS Pharmaceuticals (NASDAQ:CNSP) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 0.0% of CNS Pharmaceuticals shares are held by company insiders. Comparatively, 2.2% of KALA BIO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, KALA BIO had 2 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 3 mentions for KALA BIO and 1 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.93 beat KALA BIO's score of 0.47 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CNS Pharmaceuticals	Positive
KALA BIO	Neutral

CNS Pharmaceuticals currently has a consensus target price of $20.00, indicating a potential upside of 327.35%. KALA BIO has a consensus target price of $1,158.33, indicating a potential upside of 112,359.55%. Given KALA BIO's higher probable upside, analysts plainly believe KALA BIO is more favorable than CNS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

CNS Pharmaceuticals' return on equity of -238.68% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
KALA BIO	N/A	-1,336.10%	-94.85%

CNS Pharmaceuticals has a beta of 3.06, indicating that its share price is 206% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.35, indicating that its share price is 335% less volatile than the broader market.

Summary

KALA BIO beats CNS Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to China Pharma?

CNS Pharmaceuticals (NASDAQ:CNSP) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

CNS Pharmaceuticals has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
China Pharma	-85.56%	-63.93%	-31.42%

CNS Pharmaceuticals presently has a consensus price target of $20.00, suggesting a potential upside of 327.35%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe CNS Pharmaceuticals is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, China Pharma had 1 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 2 mentions for China Pharma and 1 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.93 beat China Pharma's score of 0.19 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CNS Pharmaceuticals	Positive
China Pharma	Neutral

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 0.0% of CNS Pharmaceuticals shares are owned by insiders. Comparatively, 6.4% of China Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

CNS Pharmaceuticals has a beta of 3.06, meaning that its stock price is 206% more volatile than the broader market. Comparatively, China Pharma has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

China Pharma has higher revenue and earnings than CNS Pharmaceuticals. China Pharma is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A
China Pharma	$3.99M	11.17	-$3.08M	-$0.55	N/A

Summary

CNS Pharmaceuticals beats China Pharma on 8 of the 15 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Evaxion A/S?

CNS Pharmaceuticals (NASDAQ:CNSP) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Evaxion A/S's return on equity of -73.56% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
Evaxion A/S	N/A	-73.56%	-37.45%

CNS Pharmaceuticals presently has a consensus price target of $20.00, suggesting a potential upside of 327.35%. Evaxion A/S has a consensus price target of $11.00, suggesting a potential upside of 260.66%. Given CNS Pharmaceuticals' higher probable upside, equities research analysts plainly believe CNS Pharmaceuticals is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Evaxion A/S had 1 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 2 mentions for Evaxion A/S and 1 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.93 equaled Evaxion A/S'saverage media sentiment score.

Company	Overall Sentiment
CNS Pharmaceuticals	Positive
Evaxion A/S	Positive

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 0.0% of CNS Pharmaceuticals shares are owned by insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

CNS Pharmaceuticals has a beta of 3.06, meaning that its stock price is 206% more volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

Evaxion A/S has higher revenue and earnings than CNS Pharmaceuticals. Evaxion A/S is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A
Evaxion A/S	$7.53M	3.38	-$7.71M	-$1.47	N/A

Summary

Evaxion A/S beats CNS Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Get CNS Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNSP vs. The Competition

Export

Metric	CNS Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.83M	$3.67B	$6.77B	$12.66B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-0.16	21.50	27.12	24.38
Price / Sales	N/A	329.26	527.94	91.95
Price / Cash	N/A	143.66	48.59	59.39
Price / Book	0.64	8.57	10.82	6.32
Net Income	-$15.85M	$23.88M	$3.59B	$331.55M
7 Day Performance	-13.33%	-2.31%	-1.20%	0.08%
1 Month Performance	-1.27%	6.40%	3.11%	-0.76%
1 Year Performance	-54.98%	53.07%	29.05%	20.67%

CNS Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNSP CNS Pharmaceuticals	3.6251 of 5 stars	$4.68 -3.7%	$20.00 +327.4%	-53.7%	$6.83M	N/A	N/A	5	Gap Down
PTPI Petros Pharmaceuticals	N/A	$0.00 -4.1%	N/A	-84.7%	$146K	$5.11M	N/A	20	Gap Down High Trading Volume
TAOX Synaptogenix	0.4116 of 5 stars	$3.63 -5.7%	N/A	N/A	$28.77M	$300K	N/A	4
KALA KALA BIO	2.0839 of 5 stars	$1.51 -1.9%	$1,018.75 +67,366.9%	-99.7%	$28.63M	N/A	N/A	30	News Coverage Analyst Downgrade Short Interest Increase
CPHI China Pharma	N/A	$0.70 +2.1%	N/A	-67.5%	$28.24M	$3.99M	N/A	250	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNSP) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CNS Pharmaceuticals (CNSP) Competitors

CNSP vs. PTPI, TAOX, KALA, CPHI, and EVAX

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

Summary

How does CNS Pharmaceuticals compare to Synaptogenix?

Summary

How does CNS Pharmaceuticals compare to KALA BIO?

Summary

How does CNS Pharmaceuticals compare to China Pharma?

Summary

How does CNS Pharmaceuticals compare to Evaxion A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNSP vs. The Competition

CNS Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CNS Pharmaceuticals (CNSP) Competitors

CNSP vs. PTPI, TAOX, KALA, CPHI, and EVAX

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

Which has more volatility & risk, CNSP or PTPI?

Which has stronger valuation & earnings, CNSP or PTPI?

Do insiders & institutionals believe in CNSP or PTPI?

Does the media favor CNSP or PTPI?

Do analysts recommend CNSP or PTPI?

Is CNSP or PTPI more profitable?

Summary

How does CNS Pharmaceuticals compare to Synaptogenix?

Which has more risk and volatility, CNSP or TAOX?

Does the media favor CNSP or TAOX?

Do insiders and institutionals believe in CNSP or TAOX?

Is CNSP or TAOX more profitable?

Do analysts recommend CNSP or TAOX?

Which has better earnings and valuation, CNSP or TAOX?

Summary

How does CNS Pharmaceuticals compare to KALA BIO?

Do institutionals & insiders believe in CNSP or KALA?

Does the media favor CNSP or KALA?

Do analysts recommend CNSP or KALA?

Which has higher valuation and earnings, CNSP or KALA?

Is CNSP or KALA more profitable?

Which has more risk & volatility, CNSP or KALA?

Summary

How does CNS Pharmaceuticals compare to China Pharma?

Is CNSP or CPHI more profitable?

Do analysts prefer CNSP or CPHI?

Does the media favor CNSP or CPHI?

Do institutionals & insiders have more ownership in CNSP or CPHI?

Which has more volatility and risk, CNSP or CPHI?

Which has preferable valuation and earnings, CNSP or CPHI?

Summary

How does CNS Pharmaceuticals compare to Evaxion A/S?

Is CNSP or EVAX more profitable?

Do analysts prefer CNSP or EVAX?

Does the media favor CNSP or EVAX?

Do institutionals & insiders have more ownership in CNSP or EVAX?

Which has more volatility and risk, CNSP or EVAX?

Which has preferable valuation and earnings, CNSP or EVAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNSP vs. The Competition

CNS Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools